Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report issued on Friday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Up 6.4 %

Shares of EGRX opened at $1.49 on Friday. The firm’s 50 day moving average price is $1.05 and its 200 day moving average price is $1.28. Eagle Pharmaceuticals has a twelve month low of $0.00 and a twelve month high of $6.37.

Hedge Funds Weigh In On Eagle Pharmaceuticals

Several hedge funds have recently bought and sold shares of the business. RBF Capital LLC lifted its position in shares of Eagle Pharmaceuticals by 11.7% in the third quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock worth $534,000 after buying an additional 14,991 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of Eagle Pharmaceuticals in the 3rd quarter valued at approximately $453,000. DGS Capital Management LLC lifted its holdings in Eagle Pharmaceuticals by 44.9% in the 3rd quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock worth $268,000 after purchasing an additional 22,239 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in Eagle Pharmaceuticals during the third quarter worth approximately $96,000. 85.36% of the stock is owned by institutional investors and hedge funds.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.